comparemela.com

Page 8 - Bluebird Bio Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Research Analysts Downgrades for December 11th (AME, ATKR, AWI, BLUE, CHUY, HAL, HPQ, HZO, IMAX, JOUT)

Research Analysts’ downgrades for Monday, December 11th: AMETEK (NYSE:AME) was downgraded by analysts at StockNews.com from a buy rating to a hold rating. Atkore (NYSE:ATKR) was downgraded by analysts at StockNews.com from a buy rating to a hold rating. Armstrong World Industries (NYSE:AWI) was downgraded by analysts at StockNews.com from a buy rating to a […]

Armstrong world industriesMiller industriesInc dailyIndustrial trustResearch analystWorld industriesAmetek incAtkore incArmstrong world industries incBluebird bio incChuys holdings incHp incMarinemax incImax coJohnson outdoors inc

US FDA approves first CRISPR-based gene therapy Casgevy for sickle cell; Lyfgenia gets nod, too

Both Vertex Pharmaceuticals Inc.’s Casgevy (exagamglogene autotemcel, exa-cel) and Bluebird Bio Inc.’s Lyfgenia (lovotibeglogene autotemcel, lovo-cel) received U.S. FDA approval Dec. 8, providing 16,000 American sickle cell patients who have recurring vaso-occlusive events with access to the first cell-based gene therapies.

United statesBluebird bio incVertex pharmaceuticals incBoth vertex pharmaceuticalsBluebird bioVertex pharmaceuticals incExagamglogene autotemcelExa celBluebird bio incLovotibeglogene autotemcelLovo celSickle cell diseaseCrispr therapeutics agVaso occlusive events

US FDA approves first gene therapies to treat patients with sickle cell disease

US FDA approves first gene therapies to treat patients with sickle cell disease
biospectrumindia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospectrumindia.com Daily Mail and Mail on Sunday newspapers.

Lyfgenia bluebird bio incDrug administrationCasgevy vertex pharmaceuticals incVertex pharmaceuticals incBluebird bio inc

Global CAR T-Cell Therapy Market to Surpass $15 Billion by

Global CAR T-Cell Therapy Market to Surpass $15 Billion by
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

Saudi arabiaUnited statesSorrento therapeutics incGilead sciences incMerck coBluebird bio incImmunotherapy instituteBristol myers squibb companyUs national library of medicineJw therapeutics shanghai co ltdJohnson services incCancer treatment centers of americaTherapy market sizeTrends analysis reportDisease indicationMultiple myeloma

FDA Approves First Gene-Editing Cell Therapy For Sickle Cell Disease, An Inherited Blood Disorder - CRISPR Therapeutics (NASDAQ:CRSP), bluebird bio (NASDAQ:BLUE), Vertex Pharmaceuticals (NASDAQ:VRTX)

The FDA has approved Casgevy and Lyfgenia, representing the first cell-based gene therapies for sickle cell disease in patients 12 y

Healthcare products regulatory agencyVertex pharmaceuticals incBluebird bio incPharmaceuticals incBio inc

vimarsana © 2020. All Rights Reserved.